Imidacloprid/moxidectin

Imidacloprid/moxidectin

Combination of
Imidacloprid	Insecticide
Moxidectin	Anthelmintic
Clinical data
Trade names	Advantage Multi, Imoxi Topical Solution, Advocate
License data	US DailyMed: Advantage multi
Routes of administration	Topical
ATCvet code	QP54AB52 (WHO)
Legal status
Legal status	CA: ℞-only[2] US: WARNING[1]Rx-only[3][4] EU: Rx-only[5][6]

Imidacloprid/moxidectin, sold under the brand names Advantage Multi for Dogs and Advantage Multi for Cats among others, is a medication for dogs and cats to treat heartworm, fleas, sarcoptic mange, intestinal parasites and ear mites.^{[7][8][9][10][3][4]}

Medical uses

Imidacloprid/moxidectin is indicated for the prevention of heartworm disease caused by Dirofilaria immitis in dogs and cats.^[11][12] Imidacloprid/moxidectin kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations in dogs and cats.^{[11][12][9][3]}

Imidacloprid/moxidectin is indicated for the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs.^[11] Imidacloprid/moxidectin is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis.^[11] Imidacloprid/moxidectin is also indicated for the treatment and control of the specific intestinal parasites.^[11] It is also indicated for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).^[11][9]

In cats, imidacloprid/moxidectin is indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).^{[4][13][10][12]}

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
2. "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
3. "Advantage Multi for Dogs- imidacloprid moxidectin solution". DailyMed. 18 April 2018. Retrieved 29 May 2020.
4. "Advantage Multi for Cats- imidacloprid and moxidectin solution". DailyMed. 18 April 2018. Retrieved 28 May 2020.
5. "Advocate EPAR". European Medicines Agency (EMA). 28 July 2009. Retrieved 29 January 2021.
6. "Advocate PI". Union Register of medicinal products. 4 April 2003. Retrieved 26 December 2024.
7. "Advantage Multi for Dogs". U.S. Food and Drug Administration (FDA). Retrieved 28 May 2020.
8. "Advantage Multi for Cats". U.S. Food and Drug Administration (FDA). Retrieved 28 May 2020.
9. "Imoxi Topical Solution for Dogs". U.S. Food and Drug Administration (FDA). Retrieved 28 May 2020. This article incorporates text from this source, which is in the public domain.
10. "Imoxi Topical Solution for Cats". U.S. Food and Drug Administration (FDA). Retrieved 28 May 2020. This article incorporates text from this source, which is in the public domain.
11. "Imoxi Topical Solution for Dogs FOIA Drug Summary". U.S. Food and Drug Administration (FDA). Retrieved 28 May 2020. This article incorporates text from this source, which is in the public domain.
12. "Imoxi Topical Solution for Cats FOIA Drug Summary". U.S. Food and Drug Administration (FDA). Retrieved 28 May 2020. This article incorporates text from this source, which is in the public domain.
13. "FDA Approves Generic Animal Drug for Parasite Protection in Cats". U.S. Food and Drug Administration (FDA) (Press release). 28 May 2020. Retrieved 28 May 2020. This article incorporates text from this source, which is in the public domain.